AAV‐mediated gene therapy of c‐terminal cleaved tau at D421 (∆D421‐tau) leads to significant neuronal loss in the CA3 area of the hippocampus and medial entorhinal cortex, which contributes to synaptic plasticity and cognitive deficits [166]. This evidence concerns the gene MAPT and Cognitive impairment.